08:00 , Dec 13, 2004 |  BC Week In Review  |  Company News

Chester Valley dermatology news

Private equity firm GTCR Golder Rauner LLC (Chicago, Ill.) will form specialty dermatology company Chester Valley Pharmaceuticals. GTCR will invest up to $75 million in the newco, which will acquire or in-license, develop and market...
08:00 , Dec 7, 2004 |  BC Extra  |  Company News

GTCR to form Chester Valley Pharmaceuticals

Private equity firm GTCR Golder Rauner will form specialty dermatology company Chester Valley Pharmaceuticals (Malvern, Penn.). GTCR will invest up to $75 million in the newco. Chester Valley will acquire or in-license, develop and market...
07:00 , Aug 16, 2004 |  BC Week In Review  |  Company News

Bradley, Quintiles, SkyePharma deal

BDY completed its previously announced acquisition of QTRN's dermatology subsidiary, Bioglan Pharmaceuticals Co. (Malvern, Penn.), for $183 million in cash (see BioCentury, June 14). The closing triggered a $5 million payment to SKP from QTRN,...
07:00 , Jun 14, 2004 |  BC Week In Review  |  Company News

Bradley, Quintiles deal

BDY will acquire dermatology company Bioglan Pharmaceuticals Co. (Malvern, Penn.) for $183 million. Bioglan, which is a wholly owned subsidiary of QTRN, posted sales of $55 million for the year ended April 30, 2004. Bioglan...
07:00 , May 20, 2002 |  BC Week In Review  |  Company News

Bioglan, Shire Pharmaceuticals Group plc, SkyePharma deal

SKP granted SHP European marketing rights to its Solaraze diclofenac, a non-steroidal anti-inflammatory drug to treat actinic keratosis, for £12.9 million ($18.9 million). SKP is eligible for an additional £2.1 million payment related to launches...
07:00 , May 20, 2002 |  BioCentury  |  Finance

Ebb & Flow

Back in February, a table in BioCentury showed how much value would be lost in big cap biotech if the group's price-to-earnings multiples contracted to those of big pharma (see BioCentury, Feb. 19). At the...
07:00 , May 13, 2002 |  BC Extra  |  Company News

Shire, SKP Solaraze deal

SkyePharma (LSE:SKP; SKYE) granted Shire (LSE:SHP; SHPGY) European marketing rights to its Solaraze diclofenac, a non-steroidal anti-inflammatory drug to treat actinic keratosis, for L12.9 million ($18.9 million). SKP is eligible for an additional L2.1 million...
07:00 , Apr 8, 2002 |  BC Week In Review  |  Company News

Bioglan, CeNeS deal

CEN said it had agreed with BGP’s administrators to terminate a 2000 distribution and marketing deal for CEN’s Moraxen morphine formulation to treat cancer pain and a separate 2000 deal for BGP to develop a...
08:00 , Apr 2, 2002 |  BC Extra  |  Company News

CeNeS terminates Bioglan deals

CeNeS (LSE:CEN) said it had agreed with the administrators of Bioglan (LSE:BGP) to terminate a 2000 distribution and marketing deal for CEN's Moraxen morphine formulation to treat cancer pain and a separate 2000 deal for...
08:00 , Mar 25, 2002 |  BC Week In Review  |  Company News

Bioglan, Quintiles Transnational Corp. deal

QTRN acquired most of the assets of Bioglan Pharma Inc., the U.S. subsidiary of BGP, for $26.7 million in cash. Included in the deal were North American marketing rights to certain dermatology products, including Adoxa...